INNOVATIVE BENEFITTING PEOPLE AND PLANET

ANNUAL REPORT 2018-2019 FOREWORD

As we approach 2030, Europe and the wider world face a broad range of challenges on the journey towards delivering on the UN Sustainable Development Goals. With increasing demands on natural resources, an aging demographic with complex healthcare needs and the threat of climate change, new solutions are needed now more than ever.

The European biotech industry is uniquely positioned to deliver and, with the right support, it will create a new spectrum of biotech products and processes, to help meet current and future needs, benefitting people and planet. Tjerk de Ruiter, The European biotech industry has already been EuropaBio Chair, CEO of Corbion. central to the development of new therapies to treat unmet medical needs, producing more food on less land with less dependence society, industry, policy makers, interest groups on resources and significantly reducing GHG and other thought leaders in order to create an emissions across many industrial sectors. innovation-based framework that enables safe and beneficial therapies and products to reach But in order to fulfil the potential of EU Biotech patients and consumers in a timely way. and usher in a new age of ‘’biologicalisation’’, alongside digitalisation, a collective EU The new and Commission commitment to a proportionate, fit-for-purpose, have the opportunity to capture the potential science-based policy approach, is essential. of innovative, value adding technologies such as biotech in Europe. Through bold political In recent years, huge progress has been made leadership, that defines and commits to in biotech with advances in genome editing the EU’s ambitions for healthier people and and gene therapy offering up new hope in planet, fostering Europe’s strengths, rather tackling some of our most devastating diseases than restricting them, they can rise to this and planetary challenges. These advances are challenge. EuropaBio and the growing European potentially game-changing, but the science community of scientists, experts, innovators has evolved much faster than policy. Open and students, working across the breadth of and inclusive dialogue is now needed with civil biotech, stand ready to support this ambition. TABLE OF CONTENTS

6 30 Cross-sector Industrial biotech

16 38 Healthcare Our team biotech

22 40 Agricultural Our members biotech CROSS-SECTOR • 6 Our positiononGenomeEditing • Biotechnology Industry • One technology -unitedin • Our Vision &Mission • HIGHLIGHTS Excelling insocialmedia • Promoting biotech innovation • Manifesto 2019 purpose from European SMEs celebrated across the continent th CROSS-SECTOR European Biotech Week policymakers and the general public. profile of European biotechnology among editing andoutreach projects to raise the intellectual property, SMEs,genome biotechnology inEurope. These include industry-wide initiatives to strengthen Associations, works onanumber of EuropaBio, with the support of itsNational industrial andagricultural biotech sectors, In addition to prioritiesin the healthcare, work cross-sectorally inpromoting thought leadership in three core areas: In addition to our healthcare, agricultural andindustrialbiotech goals,EuropaBio continues to One technology -unitedinpurpose quantity of food and feedstuff sand tomove towards abio-basedand zero-waste economy. improve quality of life, to prevent, diagnose, treat andcure diseases, to improve the quality and EuropaBio anditsmembers are committed to the socially responsible useof biotechnology to challenges. voice of the European biotech community, championing world-class solutions for society’s Our missionis for EuropaBio, the European Association for Bioindustries, to be the recognised Our Vision &Mission benefits of biotech now Innovative biotechnology benefi ttingpeopleandplanet Our vision isof: and for thefuture Developing anew narrativeon the 1 predictable approach to genomeediting science-based Establishing a 2 biotechnology strategy EU Life Sciences and creation of anew Supporting the 3

9 I ANNUAL REPORT 2018-2019 • a fact-based platform for dialogue, information sharing and trust building to be set up by the Biotechnology Industry Manifesto 2019 that brings together policy makers, public researchers, civil society and industry. In 2019, EuropaBio developed its new manifesto with the aim of: Resetting the ambition for biotechnology in the EU 6th European Biotech Week celebrated We promote fi ve guiding principles for a competitive EU biotechnology industry: 1. Sound science-based policy making across the continent 2. Fast and equitable access to innovative biotechnology products and processes 3. Fair and sustainable IntellectualResetting Property the ambition systems for biotechnology in the EU

INTRODUCTION

4. A supportive and predictable fundingOver the coming decades, it will framework The 2018 European Biotech Week, which took place between 24-30 be essential to innovate towards delivering sustainable solutions to TIME TO ENGAGE IN the broad range of challenges that Europe is facing. The biotech industry A NEW DIALOGUE can help tackle several of these AND EMBRACE signifi cantly, contributing to a more THE POTENTIAL OF resource effi cient, climate neutral and BIOTECHNOLOGY IN 5. A highly-skilled workforce in innovationall driven knowledge-basedMember States September, gathered further momentum with over 135 events EUROPE economy that improves the health and well-being of people and planet.

The complexity of Biotechnology is one of the key the technology, enabling technologies driving the combined with fourth industrial revolution. It has BIOTECHNOLOGY misinformation delivered huge advances in many and a backlash against guiding principles for a competitive 2 Build trust sectors, including healthcare, taking place in 18 diff erent countries. The #BiotechWeek was science, academia and INDUSTRY MANIFESTO 2019 industrial processes and . 2019 With its own specifi c biotech expertise have created EU biotechnology industry a. Make a step change in risk communication: the Commission and other authorities To help achieve the UN Sustainable ecosystem, Europe can take the 5 misunderstandings and unfounded should prioritise delivering the forthcoming ‘general plan for risk communication’ on Development Goals by 2030, a global lead by sustainably developing concerns about biotech. To be food safety. proportionate, fi t-for-purpose and its economy, to protect the successful, Europe’s core values of science-based approach to modern 1 Sound science-based policy making applying the precautionary principle b. Combat the spread and sources of misinformation. environment, secure jobs, improve the progress and solidarity need to be technologies, such as innovative as intended, fully implementing the innovation principle, and ensuring c. Engage in active discussions on ethical aspects of innovation by fostering a health, life expectancy and well-being applied. An open and transparent biotechnology, is essential. effi cient product authorisation systems. dialogue with industry, consumers, patients, farmers, media, investors, purchasers Our call to action asks policy makers andof European citizens. stakeholdersdialogue is critical to reinstating trust in to: INNOVATIVE BIOTECHNOLOGY BENEFITTING PEOPLE AND PLANET celebrated by a great diversity of participants, from researchers and and policy makers. sound science and policy making. 2 Fast and equitable access to innovative biotechnology products and Biotechnology is part of our everyday EuropaBio, the European Association for Bioindustries, is the recognised voice of the EU biotech community, championing world-class processes to the benefi t of patients, consumers and farmers, refl ecting a lives and off ers citizens concrete The new mandate of the European solutions for society’s challenges. EuropaBio and its members are committed to the responsible use of biotechnology to improve quality fully functioning single market. solutions. However, regulatory Parliament and Commission for 2019- of life, to prevent, diagnose, treat and cure diseases, to improve the quality and quantity of food and feedstuff s and to move towards Protect intellectual property roadblocks such as slow and 2024 will represent an opportunity to 3 a bio-based and zero-waste economy. 3 Fair and sustainable Intellectual Property systems, supporting research politicised authorisation systems reset the ambition for biotechnology and development of biotechnology-derived products and processes. for some biotech applications are in Europe. We encourage all decision a. Maintain the biotech patents directive in its current form, which is already fi t Very few other sectors enhance quality of life, knowledge, innovation, productivity and environmental protection like biotechnology. blunting Europe’s competitive edge makers at European and national level for purpose. • Foster innovation-enabling supportive measures 4 A supportive and predictable funding framework which includes a focus professionals to curious students, across all age groups. From new drugs that can address unmet medical needs and fi ght epidemics and rare diseases, to industrial processes that use renewable and are already limiting the availability to consider our call to action. on building a stronger SME and start-up biotech ecosystem and facilitating b. Strive to off er the most internationally competitive suite of IP incentives in order of and access to demonstrably safe feedstocks instead of crude oil, to drought-resistant crops that allow farmers around the world to feed more people under ever-harsher to attract investment and stimulate future innovation in the context of lengthy biotech products and processes in climatic conditions, promoting and investing in biotech pays economic, societal and environmental dividends. access to fi nance for SMEs. product authorisation processes. This should include Supplementary Protection Europe. While Europe holds a leading BIOTECHNOLOGY Certifi cates as well as other intellectual property rights and incentives for The EU’s biotech industry is led by position in some areas of biotech 5 A highly-skilled workforce in all Member States to increase products such as pharmaceuticals (e.g. Orphan Medicinal Products and Paediatric a highly-skilled community of large, research, the last decade has seen an competitiveness and meet the evolving needs of a fast-moving, innovative indications), biosimilars and crop protection products. medium and small (SMEs) research and exodus of R&D expertise and decline INDUSTRY MANIFESTO 2019biotechnology sector. and regulation development intensive businesses, in investment in the EU . c. Continue to protect confi dential business information and trade secrets, also in start-ups, scientists and academics. regulatory systems. Going forward, the key will be to Europe is lagging behind, especially retain and grow talent, encourage in the fi eld of agricultural collaboration across countries, secure biotechnology, partly due to an Resetting the ambition Establish a supportive and predictable funding framework increased investment and faster excessive emphasis on precautionary 4 uptake of innovations. policies. Precious years to innovate, Now is the time for the EU to move INDUSTRIAL invest, create jobs and bring new forward decisively, improving its HEALTHCAREfor biotechnologyAGRICULTURAL a. Prioritise easy access to funding to build a stronger SME and start-up biotech ecosystem, favouring the development of BIOTECH • Build trust solutions to patients, consumers and competitiveness on the world stage, BIOTECH BIOTECH small enterprises. EuropaBio hosted a week-long exhibition, highlighting the role CALL TO ACTION farmers have been lost. investing in sustainable growth, and b. Ensure an appropriate level of funding for the bioeconomy and biotechnology under Horizon Europe to enable the development CO mitigation potential of tackling the global challenges facing 2 A new treatment of cancer or 17 million farmers industrial biotech and bio- of new biotech solutions. a rare disease is 72% likely in the EU globally grow GM/biotech people and planet. based products between to come from an emerging crops on 189.8 million Foster innovation-enabling supportive measures and regulation c. Support translational research projects, and Joint Undertakings, in particular ensure continuation of the Bio-based Industries 1-2.5 billion tonnes of CO 189.8 million 1 2 biopharma company hectares EuropaBio, the European Association for Bioindustries equivalent per year by 2030 Joint Undertaking and the Innovative Medicines Initiative II.

EuropaBio Healthcare Built-in d. Establish a new life science fi nancing mechanism addressing both fi nancing and therapeutic gaps. Avenue de l’Armée 6, 1040 , Close to 500,000 jobs protection Members spend € 62 billion against a. Urgently take measures to ensure a science-based, predictable and fair approach to genome editing, that refl ects technological in the IB value chain and insects e. Improve coherence of diff erent fi nancing mechanisms. t. +32 2 735 03 13 | f. +32 2 735 49 60 a year on R&D = 16% • Protect intellectual property € 31.6 billion added value progress and is based on the principle of proportionality. Enable utilisation of genome editing for product development and of biotech in delivering on the UN Sustainable Development revenue Less fuel and CO www.europabio.org 2 ensure that organisms developed with precise, modern mutagenesis techniques are not subjected to disproportionate regulatory emissions - Equivalent to 1:4 job multiplier: for every EuropaBio SMEs invest close invest close saving 27.1 million tonnes requirements. job created in industrial to 150% of revenue in R&D of CO each year biotech there are 4 jobs 2 created elsewhere > 160 drugs for rare b. Ensure effi cient risk assessment, especially for products with decades of safe use, such as transgenic crops. 5 Develop a strategy for biotechnology-focussed for rare Reduced soil erosion - diseases approved inin Saving land from industrial innovation Greener transport thanks to the EU plowing and cultivation sustainable biofuels, rubber, c. Remove scientifi cally unjustifi ed regulatory requirements, especially when they contradict the EU’s policy to reduce animal testing. tyres and bioplatic parts > 3.4 million Europeans 6% to 30% more yield a. Foster strong European knowledge-based bioindustries. • Establish a supportive and predictable funding are diagnosed with cancer d. Make science-based decisions: Member States and Members of the European Parliament should support the approval of Goals, which took place in front of the European Parliament on Place Luxembourg, Brussels. Sustainable alternatives every year and b. Develop and support a new EU life sciences and biotechnology strategy to make the 30 million Less toxins in food safe products. to fossil-based products: Europeans suff er from EU a world leader in cutting edge, coherent and integrated innovation to create new bio-chemicals, plastics, seed rare diseases Helping alleviate poverty and jobs in modern bioindustries through technological progress. inoculants and pest control, etc. e. Confi rm renewed commitment to the EU bioeconomy and recognise the central role of biotechnology as an enabling technology hunger - Uplift ing the lives of 16-17 million small farmers for a more competitive, sustainable bioeconomy. c. Prioritise life sciences and biotechnology amongst the Key Enabling Technologies Solutions to improve resource and their families totaling effi ciency of industrial processes for the future in the EU Industrial Policy Strategy: a vision for 2030. > 65 million people f. Boost market uptake of innovative bio-based products and adopt measures to support their deployment, such as the rolling out of d. Create the conditions for a progressive EU innovation ecosystem, addressing full framework public procurement initiatives and measures to raise awareness of their benefi ts. value chain creation, ranging from fundamental discovery and toThe business creation opening of the exhibition was hosted by MEP Christofer Fjellner and was attended by right through to the consumer. • Develop a strategy for biotechnology-focused policymakers, scientists, industry peers and a large number of students. industrial innovation ANNUAL REPORT 2018-2019 2018-2019 REPORT ANNUAL ANNUAL REPORT 2018-2019 2018-2019 REPORT ANNUAL I I 11 10 Our position on Genome Editing

Following the EU Court of Justice ruling of 25 July 2018 on mutagenesis, EuropaBio calls upon European decision-makers to take policy action. The European Commission, should take an active role in bringing stakeholders together and should provide proportionate regulatory policies to enable Scan code innovation for developing products by genome editing methods. In April/ May to watch video 2019, an open letter on the court ruling was co-signed by 25 other leading EU industry associations and sent to the EU Member States.

To this end, EuropaBio calls for:

• science-based, predictable and proportionate rules that refl ect technical progress and that seek to ensure that organisms developed with more sustainable, precise, modern mutagenesis techniques are not subject to disproportionate regulatory requirements. 12 I ANNUAL REPORT 2018-2019 135+ events

followers @biotechweek > 2.300 taking place in KEY FIGURESFOR THE WEEK INCLUDE 18 countries www.biotechweek.org

mobilised during the weekduring the mobilised European citizens > 10.000 media pick-ups 330 @Biotechweek visits > 1.800 #BiotechWeek tweets > 1.000 9

across countries

13 I ANNUAL REPORT 2018-2019 The #BiotechSMEAwards were presented during a dinner ceremony in Brussels hosted by MEP Promoting biotech innovation Dr. Paul Rübig where each of the fi nalists took part in a ‘pitching session’. from European SMEs During the event, Deputy Director-General Wolfgang Burtscher, DG Research, Science & Innovation of the European Commission emphasised biotech as a key enabling technology and encouraged biotech SMEs to keep playing a core role in delivering on the aspirations of The 9th edition of the ‘Most Innovative European Biotech SME Awards’ recognised exceptional Horizon Europe. European small and medium sized biotech companies that developed novel and innovative ways of addressing societal, technical and environmental problems through the application of biotechnology. The 2018 award winners were Genoscience Pharma1 (Healthcare Biotech), Lactips2 (Industrial Biotech) and Phytowelt GreenTechnologies3 (Agricultural Biotech).

The 2018 award winners were:

Excelling in social media ANNUAL REPORT 2018-2019 2018-2019 REPORT ANNUAL ANNUAL REPORT 2018-2019 2018-2019 REPORT ANNUAL I From left to right: Dr. Peter Heinrich, EuropaBio SME Platform Chair; Dr. Peter Welters, CEO, Phytowelt I 15 14 GreenTechnologies; Philippe Halfon, President and Founder, Genoscience Pharma; Marie Hélène Gramatikoff , CEO, Lactips; Prof. Dr. Andrew Porter, University of Aberdeen; Cindy Khaldi, Manager Associate, Genoscience This year, EuropaBio was listed among the Top 10 out of 600 EU industry associations for its Pharma; Dr. Paul Rübig, MEP; Joanna Dupont-Inglis, EuropaBio Secretary General. profi le and visibility on three key social media platforms byCambre Associates:

Agricultural Biotech Healthcare Biotech Industrial Biotech 6th/600 with 13.596 followers category category category

10th/600 with 5.309 followers

1 Phytowelt GreenTechnologies is an SME focussing on plant-breeding projects that aim at enabling regional production of renewable resources. 9th/600 with 181.926 views It is the fi rst company able to produce a biotech raspberry fragrance in high quantity and quality without using energy ineffi cient petrochemical processes, which helps meet the big and unmet demand of the perfume, food and cosmetic markets for natural fragrances and fl avours. 2 Genoscience Pharma is an innovative SME located in Marseille, France that is in the product development phase with their therapy against cancer stem cells, which are considered to be responsible for treatment resistance and mutation. Genoscience’s drug candidate has the potential to reduce the frequency of relapse when combined with chemotherapy. 3 Lactips is specialised in the development of eco-friendly plastic raw material. Their material is the only bio-based, biodegradable, thermoplastic to be water soluble at room temperature and is made of milk proteins. These outstanding properties are brought by the industrial mastering of the transformation of milk protein into processable polymers. HEALTHCARE BIOTECH HIGHLIGHTS In the past year, EuropaBio has worked Regular consultations with patient groups to strengthen the biotech ecosystem in • Regular consultations order to enable healthcare biotechnology on EU health policy with patient groups on EU and medical innovation in Europe to health policy fl ourish. Our key goal has been to harness Europe’s scientifi c excellence to ensure the EuropaBio has hosted two discussion tables • Meeting with European treatments of the future are developed here with external stakeholders, which included Medicines Agency (EMA) and that Europe remains at the forefront of over 12 patient organisations and one payer, Executive Director, global innovation. on important issues of common interest. The Prof. Guido Rasi fi rst of the two discussions focused on EU In the coming year, we will continue to work protections and incentives for innovative • New coalition of healthcare on this by: medicines, followed by a discussion on the trade associations to work on EMA’s draft strategy on regulatory science to public private partnerships with • Promoting a European Strategy for Life 2025. As patients play an increasingly important role in the regulatory process, these discussions the European Commission Sciences at EU level provided EuropaBio with valuable insights into the patients’ vision for the future of developing scientifi c research into tangible treatments for patients. • Response to the European • Building a stakeholder coalition to Ombudsman inquiry on how the promote strengthening of the healthcare EMA engages with medicines ecosystem in Europe Meeting with European Medicines Agency developers prior to marketing authorisation application • Continuing to work with legislators, (EMA) Executive Director, Prof. Guido Rasi regulators, and healthcare systems, • Contribution to the European in order to ensure Europe maintains

In October 2018, EuropaBio met with EMA 2018-2019 REPORT ANNUAL Commission’s evaluation of an innovative regulatory environment I

the eff ects of the legislation supporting medical innovations Executive Director, Professor Guido Rasi, in 19 on Orphan Medicinal and breakthroughs order to hold an exchange of views on the Products (OMPs) current challenges and opportunities for the • Explaining the benefi ts of the biotech future of innovation in Europe. EuropaBio business model to a greater audience, emphasised the need for a strong regulatory showcasing the opportunities presented environment and a forward-thinking regulator by upcoming technologies in order to ensure we remain at the forefront of global innovation.

As a follow-up to the meeting, EuropaBio invited Professor Guido Rasi to participate at the BIO-EuropaBio EMA Roundtable meeting at the 2019 Bio International Convention in Philadelphia, 3-6 June. HEALTHCARE BIOTECH New coalition of healthcare trade Contribution to the European associations to work on public private Commission’s evaluation of the eff ects partnerships with the European Commission of the legislation on Orphan Medicinal Products (OMP)

EuropaBio worked with a number of EU trade associations in the healthcare fi eld to develop a Strategic Research Agenda aimed at providing the outline for a potential future Public Private Partnership that would off er a unique value proposition by driving pre-competitive multi- EuropaBio has been actively engaged and participated in the European Commission’s ongoing sectorial collaboration. evaluation of the OMP Regulation.

The Strategic Research Agenda is based on fi ve levers, ranging from the application of big data These activities included coordinating with members and National Associations to submit and artifi cial intelligence to enable new approaches to healthcare, to reinforcing value-based written responses, and participating in a telephone interview with the consultancy conducting healthcare and allowing for outcomes-based reimbursement of integrated care. the report. Furthermore, EuropaBio coordinated preparatory calls among members, including with other trade associations representing the innovative sector, in order to best prepare industry participation at a conference organised by the European Commission held to allow for an in-depth discussion with stakeholders on the functioning of the Regulation. ANNUAL REPORT 2018-2019 2018-2019 REPORT ANNUAL ANNUAL REPORT 2018-2019 2018-2019 REPORT ANNUAL I I 21 20

Response to the European Ombudsman In October 2018, the European Ombudsman’s offi ce opened a public consultation into the arrangements the EMA has in place for engaging with individual medicine developers before an inquiry on how the EMA engages with application for marketing authorisation is made. medicines developers prior to marketing EuropaBio submitted a detailed response to the consultation, emphasising the need for a sophisticated regulatory environment authorisation application where medicine developers and regulatory authorities interact on a continuous basis in order to shape new regulatory standards in fi elds where science is moving fast. AGRICULTURAL BIOTECH HIGHLIGHTS Genetically modifi ed (GM) crops have been widely grown and consumed for over Securing Europe’s access to GM crops 20 years. EuropaBio has been working • Securing Europe’s access to intensively to communicate their benefi ts GM crops and remove unnecessary barriers to GM 2018-19 was a special year for European agricultural biotechnology, during which we grain and soybean imports into the EU, have continued communicating on the importance of GMOs for the EU livestock sector. • Working for effi cient and and to promote EU farmers’ freedom of Amidst increasing political uncertainty, infl uenced by factors like on-going Brexit transparent risk assessment and choice. Improved regulatory certainty and negotiations and European elections, we have continued to highlight our calls for improved risk communication effi ciency of the EU’s GMO authorisation science-based decision making. In 2018, seven GMO import approvals were granted, and process are urgently needed. In reaction to timelines for approvals show slight signs of improvement. But uncertainty • Supporting science-based decision the landmark EU Court of Justice ruling of and underappreciation of GMOs remains in Europe. Through our making in agriculture & plant 25 July 2018 on mutagenesis, we also call for EU Protein Gap brochure, now translated into German breeding science-based political decision making on and Spanish, and related outreach, stakeholders have genome edited products. been informed about the benefi ts and need for agricultural • Communicating about GMOs biotechnology in Europe, including GM crops. ANNUAL REPORT 2018-2019 2018-2019 REPORT ANNUAL ANNUAL REPORT 2018-2019 2018-2019 REPORT ANNUAL I 25

Beat Späth, EuropaBio’s Agricultural Biotech Director, speaking at ‘Crop Innovation & Business’ 2019 Conference. AGRICULTURAL AGRICULTURAL BIOTECH

1

1 26 I ANNUAL REPORT 2018-2019 updated legislation. for animal welfare in testing requirements, principlesnow enshrined to someextent in the presubmission meetings for GMOapplicants,better risk communication, andimproved respect information, we have demanded improved transparency of EFSA’s internalprocedures, of EUrisk assessment for GMcrops. Whilst calling for the protection of confi dentialbusiness Parliament in April 2019, EuropaBio hasledeff orts toimprove the effi ciency andsustainability In the context of the EU’s revision of the EU food risk assessment process adopted by the EU communication risk assessment andimproved risk Working for efficient and transparent risk assessment. EuropaBio (2019). Facts must trump fear: EuropaBio responds to EUParliament vote on food chain products like GMOs. chain, includinginassessed much needed trust inour food the new rules will help to build misinformation. Wethathope precedence over fear and Science and fact must take “ communicated the importance of agricultural biotechnology. on the agri-food chain’s contributions to the UN’s SustainableDevelopment Goalsand representing 13diff erent food chainsectors across Europe, we helped toorganise a conference continuous alignment between the biotech sectors. As part of the Agri-Food ChainCoalition, relayed the strong reactions from scientistsandother stakeholders, inaddition to ensuring the ruling of 25July 2018 on mutagenesis together with other aff ectedsectors andprominently EuropaBio formulated itspositionandreaction to the game-changingEuropean Court of Justice & plant breeding decision makinginagriculture Supporting science-based agrifoodcoalition.eu #AgriFoodEU emissions. reduce energy consumption, water useandCO2 can helpincrease crop yields, lower food prices, and Agricultural biotechnology, includingGMcrops, “ AFCC (2018). How innovation contributes to the Sustainable Development Goals. court ruling that impactsgenome-edited products. to ahalt. innovation inplant breeding European Agricultural The CJEURuling will bring “ EuropaBio (2018). Statement on

27 I ANNUAL REPORT 2018-2019 28 I ANNUAL REPORT 2018-2019 during Biotech Week.during Jan Huitema(ALDE, MEP) discussing with students(left )andmovie screening anddebate of ‘Well Fed’ (right) biotech enthusiasts to discuss the need for andpotential of agricultural biotechnology. Biotechnologie) duringour 2018Biotech Week, we alsoreached out to a younger generation of with the International Plant Biotechnology Outreach cell of the VIB (Vlaams Instituut voor of approvals associated with GMOs. Through adocumentary movie screening co-organised need toimproveoutlining the efficiencyin EU food risk assessment as well as the high cost increase of followership injust 12months. We alsopublishednew andattractive factsheets GMOinfo website andrelated socialmediaaccounts, which experienced amore than 3-fold This year we boostedour communications platforms, includingour new multi-lingual Communicating about GMOs followers @GMOinfoEU > 5.600 INCREASING ENGAGEMENT @GMOinfo French andItalian including German, Multiple tweets > 7.200 EU languages

29 I ANNUAL REPORT 2018-2019 INDUSTRIAL BIOTECH HIGHLIGHTS Industrial biotech uses enzymes and micro- organisms to make bio-based products in a EuropaBio materials illustrating ways how range of sectors. It has created a powerful • EuropaBio materials illustrating toolkit of solutions that contribute to industrial biotech contributes to delivering ways how industrial biotech reducing our dependency on fossil carbon contributes to delivering the resources. the UN SDGs UN SDGs EuropaBio continues to raise awareness • #EFIB2018 of the role of industrial biotech as central The report and case studies set out the multiple roles of industrial biotech in enabling smarter, pillar of innovation and an enabler of the more effi cient use of natural resources, developing renewable alternatives to traditional • European Bioeconomy Alliance circular bioeconomy, also creating jobs, fossil-carbon products, helping to mitigate the impacts of climate change, reducing energy growth and competitiveness for Europe. consumption and man-made emissions to soil, air and water. The report includes concrete • An updated Bioeconomy Amongst other activities, we develop policy recommendations and shows how industrial biotechnology already plays a valuable role Strategy for Europe materials and messaging, contribute to in helping the EU to deliver on many of the UN Sustainable Development Goals, and that vast high level events and panels and foster potential remains for the technology to off er even greater benefi ts. • The next R&I framework collaborations with other stakeholders with programme Horizon Europe a view to obtain common objectives. and the BBI JU ANNUAL REPORT 2018-2019 2018-2019 REPORT ANNUAL I 33 INDUSTRIAL INDUSTRIAL BIOTECH 34 I ANNUAL REPORT 2018-2019 based products and processes to meet the UN SDGs. SDGs. UN the meet to processes and products based Lise Kingo, CEO andExecutive Director, UnitedNations GlobalCompact at EFIB2018. see you there.hope to we bioeconomy. of advancements andinnovations inindustrialbiotech anditsrole asanenabler of the circular academia andmedia to meet, discussandraise awareness #EFIB2018 gathered professionals from business,policy, Toulouse hosted the 11 #EFIB2018 / under thetheme congress onIndustrialBiotechnology and the Bioeconomy the EFIBexhibition featured participation of 24 start-up a Start-upwith the Village For the fi rst time, companies from 11 countries. EFIB 2019 will take place inBrussels between 30September-2 October and Industrial Biotech: Industrial th editionof EuropaBio’s annual 16-18 October 2018 Toulouse, France Delivering new bio- new Delivering John Sime AwardJohn Finland’s MetGen Oy the best innovation receivedannual the presentation. for for the Netherlands wonthe the EFIB‘pitchfest’. the third edition of Plantics BVPlantics from delegates 500+ countries from 30 OTHER FACTS &FIGURES ABOUT EFIB2018 plastics andmarinebiotechnology. such as food, feed, nutritionandhealth,bio-basedcosmetics, on topics includingsynthetic biology, new innovations in fi elds Modern Meadow, Fashion for Goodandmany others. Commission, representatives from L’Oréal, Bioserie, Anellotech, Laureate inEconomic Sciences, Wolfgang Burtscher, European including LiseKingo, UNGlobalCompact, Jean Tirole, 2014Nobel high level speakers 80+ tracks 10

35 I ANNUAL REPORT 2018-2019 European Bioeconomy Alliance An updated Bioeconomy Strategy for Europe

EuropaBio is a founding and very active member of the European Bioeconomy Alliance, a cross-sectoral alliance of 12 leading European organisations representing sectors The Commission published its updated Bioeconomy Strategy in October 2018, and EuropaBio active in the bioeconomy. Over the past year the Alliance welcomed this renewed commitment to the EU bioeconomy. EuropaBio has been active in has produced several papers, and organised events on calling for an ambitious revision of the Strategy, and together with the European Bioeconomy topics such as: Alliance actively promoted a set of joint policy asks for a strong European bioeconomy, prepared in light of the review and subsequent update of the Strategy. EuropaBio’s Joanna Dupont-Inglis • Benefi ts of the Bioeconomy: How a strong EU bioeconomy can deliver on the UN SDGs also chairs the European Bioeconomy Stakeholders’ Panel. • From research to reality: How Europe’s bioeconomy is leading the way to a truly circular economy (EBCD event) • Developing sustainable markets: the role of the circular bioeconomy in the EU (high-level panel debate at the European Industry Days)

The next R&I framework programme Horizon Europe and the BBI JU ANNUAL REPORT 2018-2019 2018-2019 REPORT ANNUAL ANNUAL REPORT 2018-2019 2018-2019 REPORT ANNUAL

I Over the coming years, investment in EU research and innovation will be essential to delivering I 37 36 solutions to a broad range of global challenges and EuropaBio promotes an appropriate level of funding for industrial biotechnology and the bioeconomy in this context.

The €3.7 billion Bio-Based Industries Joint Undertaking (BBI JU) has attracted investments, Juliette Jacques, Deputy Managing Director of Starch Europe, moderating at the EU Industry Days 2019. spurred innovation and created new value chains. In the framework of Horizon Europe it also will Members of the European Bioeconomy Alliance: be critical to build on the innovation that has been enabled and ensure a continuation of the BBI JU, something that EuropaBio is actively supporting. 38 I ANNUAL REPORT 2018-2019 PASecretary tothe General OUR TEAM & IT andOffice Manager Joanna Dupont-Inglis Finance Christine Devaux Secretary General Erica Nevius & HRManager 09/18 Since 01/19 Since Communications Manager Christopher Gallasch Agricultural Biotech Secretary General Industrial John Brennan Erica Poot Manager Biotech 08/18 02/19 Since Until Industrial Biotech Communications Administration Kai Künnecke Clara Neven Agnes Borg Assistant Assistant Director Communications &Events Pedro Narro Sanchez Public Aff airs Manager Agricultural Biotech Agricultural Biotech Clément Robijns Beat Späth Manager Director Regulatory Aff airs Regulatory Aff airs Offi cer Legal Aff airs Manager Agricultural Biotech Violeta Georgieva Petra Kostolaniova Healthcare Biotech Healthcare Biotech Agricultural Biotech Bernard Grimm Coen Frederiks Director Manager Associations &SMEManager Communications, National Administration Director Catherine DeFeyter Finance, HR&Office Healthcare Biotech Darren Kinsella Cosmin Popa Manager 07/18 12/18 Until Until

39 I ANNUAL REPORT 2018-2019 OUR MEMBERS ASSOCIATE MEMBERS AND BIO REGIONS Alkol Biotech Nanobiotix BIO NRW NovaBiotics Our membership includes a wide range of corporate and associate members, as well as bio Biosyntia Nightingale Health regions and industry associations involved in biotechnology throughout Europe. EuropaBio Cambridge Biomedical Consultants Numaferm has 49 corporate and 27 associate members and bio regions and 15 national biotechnology CHAIN Biotechnology Oryzon Genomics associations – representing some 1.800 small and medium-sized enterprises across Europe. DR. Regenold OxyMem EORTC Perseus CORPORATE MEMBERS Genoscience Pharma Phytowelt GreenTechnologies IAR Redx Pharma AbbVie Kedrion Biopharma Intellia Therapeutics SFL Pharma Ajinomoto Animal Nutrition Europe Knowledge Transfer Network Kaffe Bueno Svanvid ARD Limagrain Lactips TiGenix Amgen Merck MetGen Voisin Consulting Life Sciences ActoBio Therapeutics MolMed Medicortex Finland BASF MSD NatureWorks Biomarin Novamont Bio-on Novartis NATIONAL ASSOCIATIONS Bluebird Bio Novo Nordisk ANNUAL REPORT 2018-2019 2018-2019 REPORT ANNUAL ANNUAL REPORT 2018-2019 2018-2019 REPORT ANNUAL

Italy Assobiotec Federchimica Clariant Novozymes I I

41 40 Corbion Nestlé Spain Asebio CSL Behring Pfizer Belgium Bio.be Clementia Pharmaceuticals PTCBIO Germany Bio Deutschland Carbios Recordati Rare Diseases Ireland BioPharmaChem Dow AgroSciences Royal DSM UK Bioindustry Association DuPont SOBI Denmark Dansk Biotek Eli Lilly Syngenta Germany DIB Erytech Sanofi Genzyme Finland Finnish Bioindustries Evonik Industries Takeda Pharmaceutical France France Biotech Gilead Sciences, Inc. UniQure The Netherlands HollandBio IDEN Biotechnology Vertex Pharmaceuticals Portugal P-BIO Johnson & Johnson VectorLab Switzerland Scienceindustries Keygene ZeClinics Sweden Sweden Bio KWS SAAT SE Switzerland Swiss Biotech Association We keep working together for innovative biotechnology benefi tting people and planet! EuropaBio aisbl Avenue de l’Armée 6, 1040 Brussels, Belgium t. +32 2 735 03 13 | f. +32 2 735 49 60 www.europabio.org

This paper is made with by-products of corn and contains 30% post-use recycled fi ber, using 100% green energy.